INSTITUT CURIE

Merus announces interim clinical data for petosemtamab in r/m HNSCC, showing potential efficacy and safety. The phase 1/2 trial data, presented at ESMO Asia Congress, indicate a confirmed overall response rate of 36% with manageable safety profile. Further clinical development includes phase 3 trials in 1L and 2/3L r/m HNSCC, and phase 2 trials in mCRC, with initial data updates planned for 2025.

Stem cells rely on PIEZO1 and PIEZO2 receptors to sense mechanical forces, crucial for maintaining intestinal health. Knocking out these receptors in a preclinical model led to severe illness and rapid death, highlighting the essential role of mechanosensing in stem cell function and fate decisions.

Transgene and NEC announced 24.1-month median follow-up data from the phase I trial of TG4050, an individualized immunotherapy for head and neck cancers, showing all 16 patients treated remain disease-free. TG4050, based on Transgene’s myvac platform and NEC’s AI, demonstrated strong immunogenicity with sustained immune responses and mild adverse events. A phase II part of the trial is currently enrolling patients.

Transgene and NEC announced 24.1-month median follow-up data from a Phase I trial of TG4050 in head and neck cancer treatment, showing 16 patients remain disease-free. TG4050, an individualized immunotherapy, demonstrated strong immunogenicity and sustained immune responses with mild to moderate adverse events. The trial has expanded to a Phase I/II trial.

24.1-month follow-up data from TG4050 trial shows all treated patients remain disease-free, with sustained immune responses. A Phase II part is now enrolling patients internationally.

The RELATIVITY-104 study evaluated nivolumab, relatlimab, and platinum doublet chemotherapy as a first-line treatment for metastatic NSCLC. The combination therapy showed higher overall response rates (ORR) compared to nivolumab and chemotherapy alone, especially in patients with PD-L1 expression ≥ 1% and nonsquamous histology. The safety profile was manageable, and further studies are needed to confirm long-term benefits.

Developing a versatile AI framework utilizing network science methods to address precision medicine challenges from multi-omics data, including patient stratification, biomarker prediction, and drug repurposing for various diseases.

Nicolas Girard discusses LUMINOSITY trial results: Teliso-V monotherapy (1.9 mg/kg every 2 weeks) showed ORR of 28.6% in c-Met–overexpressing and 34.6% in c-Met–high NSCLC patients. PROs revealed improved symptoms like dyspnea, cough, and chest pain, but noted peripheral neuropathy (mostly grades 1-2, 10% grade 3+). QOL and physical functioning were maintained, with prolonged time to QOL deterioration in responders and stable disease patients. Teliso-V efficacy in late-line setting emphasizes disease stabilization's importance for QOL.

Valerio Therapeutics acquires Emglev Therapeutics to enhance drug development capabilities, leveraging Emglev's synthetic single-domain antibody (sdAb) libraries for innovative therapeutics in multiple areas, including autoimmune diseases, inflammatory disorders, and cancer.